Morgan Stanley analyst Simeon Gutman described the shift as an expansion from premiumization into medicalization, while warning that pet GLP-1s may not replicate the human markets success.
According to the authors, the findings provide an initial experimental framework for further investigation into how triple GIP/GLP-1/GCG receptor agonists may interact with brain-related pathways under diabetic conditions
A: Some people might experience digestive changes such as diarrhea, bloating, gas, or discomfort after eating fatty or high-fiber foods
The agency does not verify their safety, quality, or effectiveness
Heute stellen GLP-1-Rezeptoragonisten eine zustzliche Mglichkeit in der Therapie des Typ-2-Diabetes dar, etwa dann, wenn Metformin die erste Wahl fr die medikamentse Behandlung bei Typ-2-Diabetes nicht vertragen wird